Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome

Haematologica

Volumn 94, Issue 4, 2009, Pages 496-506

  Chamuleau, Martine E D ^a,b   Westers, Theresia M ^a   Unen, Linda Van Dre ^a   Groenland, Judith ^a   Zevenbergen, Adri ^a   Eeltink, Corien M ^a   Ossenkoppele, Gert J ^a   Van De Loosdrecht, Arjan A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Autologous cytotoxicity; Immune surveillance; Immune therapy; Lymphocytes; Myelodysplastic syndrome

Indexed keywords

GRANZYME B; LYMPHOCYTE SURFACE MARKER; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR VBETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNITY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES;

EID: 66349100779     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.13612     Document Type: Article

References (34)

1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118-29.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodys- plastic syndromes. Blood 1997;89: 2079-88.
3. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic ane- mia and myelodysplasia. Exp Hematol 2001;29:1270-7.
4. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expan- sion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25:1075-83.
5. Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, et al. Prevalence and clini- cal association of clonal T-cell expan- sions in myelodysplastic syndrome. Leukemia 2007;21:659-67.
6. Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric char- acterization of the CD4 and CD8 T- cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002;119:97-105.
7. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED, et al. Molecular strate- gies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006;108:2632-41.
8. Meers S, Vandenberghe P, Boogaerts M, Verhoef G, Delforge M. The clin- ical significance of activated lym- phocytes in patients with myelodys- plastic syndromes: a single centre study of 131 patients. Leuk Res 2008;32:1026-35.
9. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, et al. Preferential sup- pression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodys- plastic syndrome. Blood 2005;106: 841-51.
10. Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms tumor gene peptide- based immunotherapy for patients with overt leukemia from myelodys- plastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003;78:56-61.
11. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002;99:3661-7.
12. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007;109:323-30.
13. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syn- dromes. Leukemia 2006;20:463-70.
14. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, et al. Reduced natural killer (NK) func- tion associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109:4816-24.
15. Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, et al. Antithymocyte globulin and cyclosporine A as combination ther- apy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006;91:667-70.
16. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-11.
17. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syn- drome. Blood 2003;102:3025-7.
18. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007;31:727-36.
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
20. Mitelman F. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger. 2007.
21. Alessandrino EP, la Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, et al. WHO classification and WPSS predict post-transplant outcome in patients with myelodys- plastic syndrome: a study from the GITMO (gruppo italiano trapianto di midollo osseo). Blood 2008;112:895-902.
22. Westers TM, Houtenbos I, Schuurhuis GJ, Ossenkoppele GJ, van de Loosdrecht AA. Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four- color multiparameter flow cytome- try. Cytometry A 2005;66:71-7.
23. Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, Corthesy P, et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative his- tory and partial effector functions. Blood 2003;102:1779-87.
24. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-47.
25. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of nor- mal and FOXP3-mutant human T cells: FOXP3 expression without reg- ulatory T cell development. Proc Natl Acad Sci USA 2006;103:6659-64.
26. Molldrem JJ, Jiang YZ, Stetler- Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodys- plastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998;102:1314-22.
27. Ogata K, Yoshida Y. Clinical implica- tions of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma 2005;46:1269-74.
28. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate- 1-risk myelodysplastic syndromes by flow cytometry. Blood 2008;111: 1067-77.
29. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immuno- suppression. Blood 2002;100:3639-45.
30. Epling-Burnette PK, Bai F, Painter JS, Rollison D, Salih HR, Krusch M, et al. Reduced natural killer (NK) func- tion associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109:4816-24.
31. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11.
32. Wang X, Zheng J, Liu J, Yao J, He Y, Li X, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005;75: 468-76.
33. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110:847-50.
34. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007;19:224-31.